Appeals Court Backs Gilead, Bars Overseas Drug Imports by AFP Firms

A U.S. appeals court has delivered a significant legal victory to Gilead Sciences, ruling that companies operating as alternative funding programs cannot import the pharmaceutical giant's medications from overseas markets. The decision strikes a direct blow at a cost-management strategy that some employers and insurers had increasingly turned to as a way to reduce prescription drug spending.

Alternative funding programs, commonly known as AFPs, have grown in popularity in recent years as a mechanism for bypassing domestic drug prices — which are often dramatically higher than what the same medications fetch in countries with government-negotiated pricing. By sourcing drugs internationally, these programs promise savings to plan sponsors, though drugmakers like Gilead have fiercely opposed the practice on both legal and commercial grounds.

Read more Israeli Settlers Divert Palestinian Water Supply for West Bank Pool →

The ruling represents a meaningful setback for the AFP industry, which has argued that importing brand-name drugs benefits patients and self-insured employers struggling under the weight of rising healthcare costs. With the appeals court now firmly siding with Gilead, the legal pathway for such importation schemes has narrowed considerably, raising questions about the future viability of AFP business models that depend on international sourcing.

The broader implications extend beyond Gilead alone. Other major pharmaceutical manufacturers watching this case may now feel emboldened to pursue similar legal action against AFPs importing their own branded treatments. For employers and benefits administrators who had embraced AFP arrangements as a financial lifeline, the ruling forces an urgent reassessment of alternative cost-containment strategies for high-priced specialty drugs.

Continue reading at US Top News and Analysis.